J
Jaguar Health, Inc.
JAGXCIK 0001585608NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
$11.51M
Net Income
$-54.00M
Total Assets
$38.32M
Equity
$-18.69M
Shares Out
171.35M
Op. Cash Flow
$-23.69M
Business
Jaguar Health, Inc. develops and commercializes prescription drugs derived from plants for gastrointestinal and mental health conditions. Its lead product Mytesi (crofelemer) is FDA-approved for noninfectious diarrhea in HIV/AIDS patients and licensed to Future Pak for U.S. distribution. The company develops crofelemer powder for rare intestinal failure conditions and operates subsidiaries in the EU; it also holds a joint venture with Filament Health for plant-based mental health drug development.
Summary from 10-K filed 2026-04-07
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue, net | 12 | 12 | 10 | 12 | 4 | |
| Cost of product revenue | 4 | 2 | 2 | 2 | 2 | |
| Research and development | 25 | 17 | 19 | 18 | 15 | |
| Sales and marketing | 9 | 8 | 6 | 9 | 9 | |
| General and administrative | 19 | 16 | 17 | 18 | 17 | |
| Impairment loss on indefinite-lived intangible assets | 800,000 | — | 371,000 | — | — | |
| Total operating expenses | 57 | 43 | 44 | 46 | 45 | |
| Loss from operations | −46 | −31 | −34 | −34 | −41 | |
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | −6 | −9 | −5 | −20,000 | −2 | |
| Gain (loss) on extinguishment of debt | −2 | 1 | 4 | −2 | −753,000 | |
| Interest income (expense) | −67,000 | −231,000 | −6 | −13 | −8 | |
| Other income (expense) | 43,000 | 51,000 | 200,000 | 950,000 | −765,000 | |
| Loss before income tax expense | −54 | −39 | −42 | −48 | −53 | |
| Income tax expense | 0 | 0 | 0 | — | 0 | |
| Net loss | −54 | −39 | −42 | −48 | −53 | |
| Net loss attributable to noncontrolling interest | −563,000 | −759,000 | −601,000 | −941,000 | −5,000 | |
| Deemed dividend to preferred stockholders | −141,000 | 0 | — | — | — | |
| Net loss attributable to common stockholders | −54 | −38 | −41 | −47 | −53 | |
| Net loss per share, basic | −22.97 | −130.69 | −2,678 | −36.18 | −88.22 | |
| Net loss per share, diluted | −22.97 | −130.69 | −2,678 | −36.18 | −88.22 | |
| Weighted-average common stock outstanding, basic | 2 | 294,534 | 15,421 | 1 | 596,154 | |
| Weighted-average common stock outstanding, diluted | 2 | 294,534 | 15,421 | 1 | 596,154 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 968,000 | 8 | 6 | 5 | 17 | |
| Restricted cash | 7 | 0 | — | — | — | |
| Accounts receivable, net | 2 | 2 | 2 | 2 | 2 | |
| Other receivable | 177,000 | 120,000 | 217,000 | 588,000 | 435,000 | |
| Inventory, net | 9 | 10 | 9 | 7 | 5 | |
| Prepaid expenses and other current assets | 2 | 12 | 10 | 7 | 4 | |
| Total current assets | 20 | 32 | 28 | 22 | 28 | |
| Property and equipment, net | 463,000 | 464,000 | 496,000 | 557,000 | 650,000 | |
| Operating lease - right-of-use asset | 1 | 936,000 | 1 | 1 | 1 | |
| Intangible assets, net | 16 | 18 | 20 | 22 | 23 | |
| Other assets | 494,000 | 1 | 1 | 995,000 | 446,000 | |
| Total assets | 38 | 53 | 51 | 47 | 53 | |
| Accounts payable | 9 | 5 | 5 | 6 | 5 | |
| Accrued liabilities | 4 | 2 | 4 | 8 | 7 | |
| Deferred revenue | 170,000 | 170,000 | — | — | — | |
| Operating lease liability, current | 192,000 | 299,000 | 348,000 | 483,000 | 240,000 | |
| Notes payable, net of discount (includes note designated at Fair Value Option amounting to $26.2 million as of December 31, 2025, and $11.9 million as of December 31, 2024, respectively) | 27 | 12 | 5 | 16 | 3 | |
| Total current liabilities | 41 | 20 | 14 | 30 | 15 | |
| Operating lease liability, net of current portion | 892,000 | 686,000 | 886,000 | 725,000 | 919,000 | |
| Deferred revenue, net of current portion | 382,000 | 553,000 | — | — | — | |
| Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $5.7 million as of December 31, 2025, and $23.5 million as of December 31, 2024, respectively) | 15 | 24 | 31 | 18 | 25 | |
| Total liabilities | 57 | 44 | 46 | 49 | 41 | |
| Commitments and contingencies (See Note 5) | — | — | — | — | — | |
| Additional paid-in capital | 381 | 354 | 314 | 267 | 231 | |
| Noncontrolling interest | −1 | −791,000 | −64,000 | −699,000 | 242,000 | |
| Accumulated deficit | −400 | −346 | −308 | −267 | −219 | |
| Accumulated other comprehensive loss | −833,000 | −467,000 | −652,000 | −680,000 | — | |
| Total stockholders' equity (deficit) | −19 | 6 | 5 | −1 | 12 | |
| Total liabilities, redeemable preferred stock and stockholders' equity (deficit) | 38 | 53 | 51 | 47 | 53 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | 6 | 9 | 5 | 21,000 | 2 | |
| Provision for inventory obsolescence | 2 | — | — | — | — | |
| Depreciation and amortization expenses | 2 | 2 | 2 | 2 | 2 | |
| Stock-based compensation, vested and released restricted stock units, and exercised stock options | 831,000 | 2 | 2 | 3 | 4 | |
| Amortization of operating lease - right-of-use asset | 289,000 | 458,000 | 375,000 | 311,000 | 94,000 | |
| Share in joint venture's loss | 162,000 | 138,000 | 51,000 | — | — | |
| Amortization of debt issuance costs, debt discount, and non-cash interest expense | 153,000 | 274,000 | 13 | 12 | 5 | |
| Shares issued in exchange for services | — | 9,000 | 171,000 | 823,000 | 16,000 | |
| Accounts receivable | 6,000 | 440,000 | −88,000 | −170,000 | 3 | |
| Other receivable | −45,000 | 86,000 | 386,000 | −251,000 | −407,000 | |
| Inventory | −254,000 | −1 | −2 | −2 | −2 | |
| Prepaid expenses and other current assets | 11 | −2 | −5 | −2 | −796,000 | |
| Other assets | 1 | −336,000 | −17,000 | — | — | |
| Accounts payable | 3 | 328,000 | −855,000 | 902,000 | 158,000 | |
| Accrued liabilities | 2 | −1 | −3 | −360,000 | 3 | |
| Deferred revenue | −171,000 | 723,000 | — | — | — | |
| Operating lease liability | −272,000 | −451,000 | −394,000 | −315,000 | −19,000 | |
| Total cash used in operating activities | −24 | −29 | −33 | −33 | −35 | |
| Purchase of furniture and fixtures | −41,000 | — | — | — | — | |
| Purchase of intangible assets | — | −215,000 | — | −2 | — | |
| Purchase of equipment | — | −16,000 | — | −77,000 | −6,000 | |
| Total cash used in investing activities | −41,000 | −231,000 | — | −2 | −6,000 | |
| Proceeds from issuance of shares in At the Market offering, net of issuance and offering costs of $145 and $157 in 2025 and 2024, respectively | 6 | 31 | 32 | 20 | 9 | |
| Proceeds from Convertible Notes | 3 | — | — | — | — | |
| Proceeds from issuance of preferred shares in PIPE financing, net of issuance cost | 2 | — | 611,000 | — | — | |
| Repayment of insurance financing | −652,000 | −608,000 | −853,000 | −1 | −943,000 | |
| Payment of Tempesta Note | −50,000 | −100,000 | −100,000 | −100,000 | — | |
| Payment of Convertible Notes | −50,000 | — | — | — | — | |
| Proceeds from issuance of common shares in exchange for License Agreement | — | 1 | — | — | — | |
| Total cash provided by financing activities | 24 | 31 | 34 | 23 | 44 | |
| Effects of foreign exchange rate changes on assets and liabilities | −113,000 | −54,000 | 15,000 | 16,000 | — | |
| Net increase (decrease) in cash and restricted cash | −170,000 | 2 | 1 | −12 | 9 | |
| Cash paid for interest | 22,000 | 14,000 | 35,000 | 23,000 | 28,000 | |
| First Insurance Financing | 681,000 | 519,000 | 676,000 | 1 | — | |
| Recognition of operating lease - right-of-use asset and operating lease liability | 341,000 | 221,000 | 30,000 | 365,000 | 1 | |
| Umbrella Insurance Financing | — | 52,000 | 110,000 | 1 | 1 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Jaguar Health, Inc.'s CIK number?
Jaguar Health, Inc.'s SEC CIK number is 0001585608 (1585608). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Jaguar Health, Inc.'s SEC filings?
All of Jaguar Health, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Jaguar Health, Inc. last report earnings?
Jaguar Health, Inc. (JAGX) most recently filed an earnings 8-K with the SEC on May 20, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-232722). This is Jaguar Health, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Jaguar Health, Inc.'s most recent earnings 8-K?
Jaguar Health, Inc.'s latest earnings 8-K (Item 2.02) was filed May 20, 2026 under accession 0001193125-26-232722. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Jaguar Health, Inc.'s latest earnings 8-K →
Look up any company's CIK number →